Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US5204450A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 9, 1990 |
| Grant date | Apr 20, 1993 |
| Priority date | — |
| Expiry date | Jan 9, 2010 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/828
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a glycoprotein, CORA, which has a binding affinity for carcinoembryonic antigen (CEA). This glycoprotein is a marker for carcinoma, and can be characterized by having a molecular weight of about 46,000-50,000 daltons, an isoelectric point of about 3.0-3.5, a carbohydrate content of about 25-35% by weight, reactivity with antisera raised thereto, and substantially no reactivity with antisera raised to nonspecific cross-reacting antigen (NCA) or to CEA. Also disclosed are a hybridoma which produces a monoclonal antibody to CORA, the monoclonal antibody to CORA, and a device, kit, and method for detecting and monitoring carcinoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.